Get the Stockscreener App
3.42
6.04%
-0.22
Immunitybio Inc stock is traded at $3.42, with a volume of 5.15M.
It is down -6.04% in the last 24 hours and up +6.21% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$3.64
Open:
$3.66
24h Volume:
5.15M
Relative Volume:
0.87
Market Cap:
$2.50B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-3.5258
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-5.52%
1M Performance:
+6.21%
6M Performance:
-22.27%
1Y Performance:
-26.92%
1-Day Range:
$3.40
$3.75
1-Week Range:
$3.35
$4.27
52-Week Range:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
3.42 | 2.50B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Why ImmunityBio (IBRX) Is Surging Today - MSN
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio cleared to bring alternative BCG treatment source amid Merck shortage - MSN
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer - Yahoo
FDA approves expanded access for ImmunityBio's bladder cancer drug By Investing.com - Investing.com South Africa
Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? - Yahoo Finance
Sector Update: Health Care Stocks Advance Late Afternoon - TradingView
Sector Update: Health Care -February 19, 2025 at 03:41 pm EST - Marketscreener.com
ImmunityBio stock gains as FDA clears Merck rival (IBRX:NASDAQ) - Seeking Alpha
FDA Authorizes Immunitybio To Provide Rbcg To Urologists -February 19, 2025 at 10:16 am EST - Marketscreener.com
Why ImmunityBio’s Stock is Gaining Attention - TipRanks
FDA Authorizes ImmunityBio To Provide Recombinant Bcg (Rbcg) To Urologists To Address Tice® Bcg Shortage - Marketscreener.com
ImmunityBio Gets FDA Authorization for Expanded Access to Recombinant BCG for Bladder Cancer Treatment - Marketscreener.com
FDA approves expanded access for ImmunityBio's bladder cancer drug - Investing.com
Critical BCG Shortage Solution: FDA Grants Access to New Treatment SourceWhat Urologists Should Know - StockTitan
FDA Allows Use of Recombinant BCG Through Expanded Access Program - Monthly Prescribing Reference
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins - Baystreet.ca
ImmunityBio (NASDAQ:IBRX) Trading 12.6% HigherStill a Buy? - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio's Application for Anktiva Approved for Review in UK -February 13, 2025 at 03:38 pm EST - Marketscreener.com
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio announces executive compensation updates By Investing.com - Investing.com Canada
ImmunityBio announces executive compensation updates - MSN
ImmunityBio Approves 2024 Executive Bonuses and New Incentives - TipRanks
Major Regulatory Win: ImmunityBio's Cancer Drug ANKTIVA Advances in UK After US Success - StockTitan
Why Immunitybio Inc. (IBRX) Soared on Thursday - MSN
Natural Killer Cell Therapies Clinical and Non-Clinical - openPR
ImmunityBio (NASDAQ:IBRX) Shares Down 6.8%Time to Sell? - MarketBeat
ImmunityBio board member John Brennan resigns - MSN
ImmunityBio board member John Brennan resigns By Investing.com - Investing.com South Africa
IBRX 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action - ACCESS Newswire
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.8%Should You Sell? - MarketBeat
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - MSN
ImmunityBio (NASDAQ:IBRX) Shares Up 17.2%Time to Buy? - MarketBeat
ImmunityBio and BeiGene ink research collaboration - The Pharma Letter
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva - BioSpace
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025 - Insider Monkey
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo - Yahoo Finance
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism - MSN
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch
Why ImmunityBio Stock is Gaining Momentum - TipRanks
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy - Marketscreener.com
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital - MarketBeat
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):